Primer Capital and Bayer became partners to support biotech start-ups23 October 2017 Primer Capital, a venture capital biotech fund, and pharmaceutical company Bayer signed an agreement to work together in the search for promising pharmaceutical and biomedical projects.
The agreement covers projects related to therapeutic areas that are priorities for Bayer, i.e. oncology, cardiology, ophthalmology and women’s health. Bayer will focus on a scientific assessment of projects while Primer Capital will be carrying out an investment expertise.
This cooperation is supported by the CoLaborator project organized through the biology department of the Lomonosov Moscow State University. The project aims to support research companies at early stages of their development.
“This partnership will not only give us further access to university developments, but will also provide additional scientific review by Bayer experts,” comments Primer Capital COO Elizaveta Rozhdestvenskaya.
Back to the list